Roche acquires InterMune for $8.3B
Switzerland's Roche Holding AG on Sunday extended a summer of dealmaking with an agreement to buy InterMune Inc. for $8.3 billion to expand its treatments for respiratory ailments.
Roche, of Basel, would pay $74 per InterMune share, a 38% bonus to the target's Friday close. The price is also a 64% bump to the stock's close Aug. 12, the day before rumors of a strategic review at the target surfaced.
Acquisitive Roche is hoping to cash in on the pending U.S. approval of InterMune's pir...